L
4.29
0.34 (8.48%)
| Previous Close | 3.95 |
| Open | 4.04 |
| Volume | 1,186,162 |
| Avg. Volume (3M) | 2,667,875 |
| Market Cap | 366,754,816 |
| Price / Book | 3.06 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -1.51 |
| Total Debt/Equity (MRQ) | 3.37% |
| Current Ratio (MRQ) | 7.48 |
| Operating Cash Flow (TTM) | -86.89 M |
| Levered Free Cash Flow (TTM) | -52.86 M |
| Return on Assets (TTM) | -31.47% |
| Return on Equity (TTM) | -50.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Larimar Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
-0.5
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.43% |
| % Held by Institutions | 103.11% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 21.00 (Oppenheimer, 390.08%) | Buy |
| Median | 14.50 (238.39%) | |
| Low | 7.00 (Baird, 63.36%) | Buy |
| Average | 14.25 (232.56%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 3.60 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 02 Oct 2025 | 21.00 (390.08%) | Buy | 4.28 |
| Baird | 30 Sep 2025 | 7.00 (63.36%) | Buy | 3.23 |
| Wedbush | 30 Sep 2025 | 11.00 (156.71%) | Buy | 3.23 |
| JMP Securities | 19 Aug 2025 | 18.00 (320.07%) | Buy | 3.65 |
| 15 Aug 2025 | 18.00 (320.07%) | Buy | 4.01 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Sep 2025 | Announcement | Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia |
| 28 Sep 2025 | Announcement | Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia |
| 14 Aug 2025 | Announcement | Larimar Therapeutics Reports Second Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |